Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. / Plauborg, Anne Veie; Hansen, Anne Vinkel; Garne, Ester.

In: Birth Defects Research. Part A: Clinical and Molecular Teratology, Vol. 106, No. 6, 06.2016, p. 494-499.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Plauborg, AV, Hansen, AV & Garne, E 2016, 'Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease', Birth Defects Research. Part A: Clinical and Molecular Teratology, vol. 106, no. 6, pp. 494-499. https://doi.org/10.1002/bdra.23509

APA

Plauborg, A. V., Hansen, A. V., & Garne, E. (2016). Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. Birth Defects Research. Part A: Clinical and Molecular Teratology, 106(6), 494-499. https://doi.org/10.1002/bdra.23509

Vancouver

Plauborg AV, Hansen AV, Garne E. Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. Birth Defects Research. Part A: Clinical and Molecular Teratology. 2016 Jun;106(6):494-499. https://doi.org/10.1002/bdra.23509

Author

Plauborg, Anne Veie ; Hansen, Anne Vinkel ; Garne, Ester. / Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease. In: Birth Defects Research. Part A: Clinical and Molecular Teratology. 2016 ; Vol. 106, No. 6. pp. 494-499.

Bibtex

@article{8ee7183ac8f34be68592c032b4f72428,
title = "Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease",
abstract = "Background: The aim of this study was to describe prescription patterns for azathioprine and corticosteroids for pregnant women with inflammatory bowel diseases (IBD) before, during, and after pregnancy and to describe pregnancy outcomes.Methods: A cohort composed of all singleton pregnancies in Danish registries from 1996 to 2009 was divided by maternal IBD status: Crohn's disease (CD, n = 827), ulcerative colitis (UC, N = 1361), or no IBD diagnosis (background population, n = 814,231). The number of women with a prescription for azathioprine, local and systemic steroids within a 3-month period was computed for each of the pregnancy trimesters and the year before and after pregnancy. Outcomes of interest were stillbirth, perinatal mortality, low birth weight (LBW), preterm birth, and small for gestational age (SGA).Results: Number of prescriptions for azathioprine decreased just before and during pregnancy and increased after birth. Number of prescriptions for local and systemic corticosteroids decreased approximately 30{\%} compared with before pregnancy and increased in the second trimester. There was an increased risk among mothers with IBD of LBW (adjusted odds ratio [adjOR]: CD: 2.25 [95{\%} confidence interval {CI}, 1.74–2.91], UC: 1.81 [95{\%} CI, 1.42–2.30]), preterm birth (adjOR: CD: 2.54 [95{\%} CI, 2.04–3.15], UC: 1.86 [95{\%} CI, 1.52–2.27]), and SGA (adjOR: CD: 1.99 [95{\%} CI, 1.26–3.15], UC: 1.80 [95{\%} CI, 1.18–2.75]).Conclusion: Use of azathioprine and corticosteroids was often reduced or discontinued before or during early pregnancy followed by an increased use of corticosteroids later in pregnancy. Women diagnosed with IBD and with prescriptions for azathioprine and/or corticosteroids, have an increased risk of LBW, pre-term birth, and SGA.",
keywords = "inflammatory bowel disease, pregnancy, birth outcome, azathioprine, coricoseroicis",
author = "Plauborg, {Anne Veie} and Hansen, {Anne Vinkel} and Ester Garne",
year = "2016",
month = "6",
doi = "10.1002/bdra.23509",
language = "English",
volume = "106",
pages = "494--499",
journal = "Birth Defects Research",
issn = "0270-3211",
publisher = "Wiley",
number = "6",

}

RIS

TY - JOUR

T1 - Use of azathioprine and corticosteroids during pregnancy and birth outcome in women diagnosed with inflammatory bowel disease

AU - Plauborg, Anne Veie

AU - Hansen, Anne Vinkel

AU - Garne, Ester

PY - 2016/6

Y1 - 2016/6

N2 - Background: The aim of this study was to describe prescription patterns for azathioprine and corticosteroids for pregnant women with inflammatory bowel diseases (IBD) before, during, and after pregnancy and to describe pregnancy outcomes.Methods: A cohort composed of all singleton pregnancies in Danish registries from 1996 to 2009 was divided by maternal IBD status: Crohn's disease (CD, n = 827), ulcerative colitis (UC, N = 1361), or no IBD diagnosis (background population, n = 814,231). The number of women with a prescription for azathioprine, local and systemic steroids within a 3-month period was computed for each of the pregnancy trimesters and the year before and after pregnancy. Outcomes of interest were stillbirth, perinatal mortality, low birth weight (LBW), preterm birth, and small for gestational age (SGA).Results: Number of prescriptions for azathioprine decreased just before and during pregnancy and increased after birth. Number of prescriptions for local and systemic corticosteroids decreased approximately 30% compared with before pregnancy and increased in the second trimester. There was an increased risk among mothers with IBD of LBW (adjusted odds ratio [adjOR]: CD: 2.25 [95% confidence interval {CI}, 1.74–2.91], UC: 1.81 [95% CI, 1.42–2.30]), preterm birth (adjOR: CD: 2.54 [95% CI, 2.04–3.15], UC: 1.86 [95% CI, 1.52–2.27]), and SGA (adjOR: CD: 1.99 [95% CI, 1.26–3.15], UC: 1.80 [95% CI, 1.18–2.75]).Conclusion: Use of azathioprine and corticosteroids was often reduced or discontinued before or during early pregnancy followed by an increased use of corticosteroids later in pregnancy. Women diagnosed with IBD and with prescriptions for azathioprine and/or corticosteroids, have an increased risk of LBW, pre-term birth, and SGA.

AB - Background: The aim of this study was to describe prescription patterns for azathioprine and corticosteroids for pregnant women with inflammatory bowel diseases (IBD) before, during, and after pregnancy and to describe pregnancy outcomes.Methods: A cohort composed of all singleton pregnancies in Danish registries from 1996 to 2009 was divided by maternal IBD status: Crohn's disease (CD, n = 827), ulcerative colitis (UC, N = 1361), or no IBD diagnosis (background population, n = 814,231). The number of women with a prescription for azathioprine, local and systemic steroids within a 3-month period was computed for each of the pregnancy trimesters and the year before and after pregnancy. Outcomes of interest were stillbirth, perinatal mortality, low birth weight (LBW), preterm birth, and small for gestational age (SGA).Results: Number of prescriptions for azathioprine decreased just before and during pregnancy and increased after birth. Number of prescriptions for local and systemic corticosteroids decreased approximately 30% compared with before pregnancy and increased in the second trimester. There was an increased risk among mothers with IBD of LBW (adjusted odds ratio [adjOR]: CD: 2.25 [95% confidence interval {CI}, 1.74–2.91], UC: 1.81 [95% CI, 1.42–2.30]), preterm birth (adjOR: CD: 2.54 [95% CI, 2.04–3.15], UC: 1.86 [95% CI, 1.52–2.27]), and SGA (adjOR: CD: 1.99 [95% CI, 1.26–3.15], UC: 1.80 [95% CI, 1.18–2.75]).Conclusion: Use of azathioprine and corticosteroids was often reduced or discontinued before or during early pregnancy followed by an increased use of corticosteroids later in pregnancy. Women diagnosed with IBD and with prescriptions for azathioprine and/or corticosteroids, have an increased risk of LBW, pre-term birth, and SGA.

KW - inflammatory bowel disease

KW - pregnancy

KW - birth outcome

KW - azathioprine

KW - coricoseroicis

U2 - 10.1002/bdra.23509

DO - 10.1002/bdra.23509

M3 - Journal article

VL - 106

SP - 494

EP - 499

JO - Birth Defects Research

JF - Birth Defects Research

SN - 0270-3211

IS - 6

ER -

ID: 164210660